secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2026-01-02T23:59:59+00:00
Accession:  0001104659-26-000209
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio terminates prior Stone Peach/BAFFX17 agreements, issues 8.66M shares to Athanor Capital
--------------------------------------------------------------------------------

- Terminated Letter Agreements with Stone Peach and BAFFX17; entered new Athanor Agreement on Dec 29, 2025.
- Issued 8,657,402 Class A ordinary shares to Athanor; $7.325M upfront fee and $25M milestone payment on change of control or first regulatory approval.
- Athanor receives piggyback registration rights and 2% net sales royalty on tibulizumab (ZB-106) from the Lilly license.
- Audit Subcommittee review completed; no financial statement impact or employee misconduct found.
- New terms deemed more commercially advantageous; prior agreements voided with broad releases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926000209/0001104659-26-000209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926000209/tm2531128d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-000209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer